Bo Jiang

Bo Jiang

Auto-generated profile, based on publicly available information

Bo Jiang

Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KAKeiko Akagi
Keiko Akagi
DSDavid E. Symer
David E. Symer
MMMedhat Mahmoud
Medhat Mahmoud
BJBo Jiang
Bo Jiang
SGSara Goodwin
Sara Goodwin
MGMaura L. Gillison
Maura L. Gillison
The human papillomavirus (HPV) genome is integrated into host DNA in most HPV-positive cancers, but the consequences for chromosomal integrity are unknown. Continuous long-read sequencing of oropharyngeal cancers and cancer cell lines identified a previously undescribed form of structural variation, “heterocateny,” characterized by diverse, interrelated, and repetitive patterns of concatemerized virus and host DNA segments within a cancer. Unique breakpoints shared across structural variants facilitated stepwise reconstruction of their evolution from a common molecular ancestor. This analysis revealed that virus and virus–host concatemers are unstable and, upon insertion into and excision from chromosomes, facilitate capture, amplification, and recombination of host DNA and chromosomal rearrangements. Evidence of heterocateny was detected in extrachromosomal and intrachromosomal DNA. These findings indicate that heterocateny is driven by the dynamic, aberrant replication and recombination of an oncogenic DNA virus, thereby extending known consequences of HPV integration to include promotion of intratumoral heterogeneity and clonal evolution. Significance: Long-read sequencing of HPV-positive cancers revealed “heterocateny,” a previously unreported form of genomic structural variation characterized by heterogeneous, interrelated, and repetitive genomic rearrangements within a tumor. Heterocateny is driven by unstable concatemerized HPV genomes, which facilitate capture, rearrangement, and amplification of host DNA, and promotes intratumoral heterogeneity and clonal evolution. See related video: https://vimeo.com/845407469 See related commentary by McBride and White, p. 814. This article is highlighted in the In This Issue feature, p. 799

9 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
XJXianli Jiang
Xianli Jiang
NRNils-Petter Rudqvist
Nils-Petter Rudqvist
BJBo Jiang
Bo Jiang
SYShengbin Ye
Shengbin Ye
SHShan He
Shan He
MGMaura L. Gillison
Maura L. Gillison
In a phase II trial, patients with local-regionally advanced human papillomavirus–positive oropharyngeal carcinoma (n = 35) received ipilimumab (anti-CTLA4) and nivolumab (anti–PD-1) as induction immunotherapy and concurrently with radiotherapy (NCT03799445). Coprimary endpoints included 6-month complete metabolic response rate (94%) and 2-year progression-free survival (84%). Induction yielded a 46% major histopathologic response rate. Single-cell profiling revealed responders had higher baseline intratumoral CD8+ T cells with a tumor-reactive, tissue-resident memory (TRM) phenotype and a treatment-related decrease in effector regulatory T (eTreg) cells. The eTreg decrease correlated with CD8+ T-cell clonotype transitioning from TRM to effector memory and IFNG+ effector cells. In nonresponders, clonotypes transitioned to exhausted TRM and proliferating cells. Multivariable regression modeling determined that the baseline feature most associated with reduction in tumor viability was the proportion of FCGR3A-expressing NK cells, which are capable of ipilimumab-dependent depletion of CTLA4high eTregs. eTreg depletion may be critical for major response to induction dual immune checkpoint blockade (ICB). Significance: The relative contributions of CD28 costimulation restoration versus Treg depletion to clinical response to CTLA4 ICB is a matter of considerable controversy. In this study, we provide compelling data that eTreg depletion is critical to tumor clearance in patients treated with dual PD-1 and CTLA4 ICB.

6 February 2018 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
YWYang-Kun Wang
Yang-Kun Wang
SWSu-Nan Wang
Su-Nan Wang
YLYing-Ying Li
Ying-Ying Li
GWGong-Ping Wang
Gong-Ping Wang
TYTian Yun
Tian Yun
MZmeiling Zhu
meiling Zhu
OBJECTIVE: This study aims to investigate the significance of combined detection of HER2 gene amplification and chemosensitivity in gastric cancer. METHODS: Immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and fluorescence revers

14 May 2025 in Cancer Discovery
Verified
Journal Article
Closed access
NKNusrat Khan
Nusrat Khan
KAKeiko Akagi
Keiko Akagi
SJShiming Jiang
Shiming Jiang
JDJoe Dan Dunn
Joe Dan Dunn
BJBo Jiang
Bo Jiang
MGMaura L. Gillison
Maura L. Gillison
Human papillomavirus (HPV) integration disrupts host genomic structure and expression, but whether these alterations promote cancer development remains unclear. Multiple genomic analyses of oropharyngeal cancers identified several host fusion genes, including recurrent FGFR3-TACC3 fusions, expressed from rearranged genomic loci adjacent to HPV integration sites. Evolutionary modeling pointed to integration of virus concatemers into the host genome as a common initiating event in fusion formation. Coexpression of HPV16 E6/E7 and FGFR3–TACC3, but neither alone, was sufficient for tumor development in both xenograft and syngeneic mouse models and led to unique transcriptional programs implicated in carcinogenesis. FGFR3–TACC3 expression decreased the ubiquitination and degradation of E6 and E7, thereby increasing oncoprotein abundance. We conclude that expression of HPV16 oncoproteins and host–gene fusions generated from HPV integration sites can be sufficient for cancer development. Significance: Fusion genes are frequently cancer drivers, but the molecular mechanisms underlying their formation have remained unclear. In this study, we identified HPV integration as the instigator of genomic rearrangements that lead to the formation of FGFR3–TACC3 and other fusion genes. FGFR3–TACC3 expression decreased the ubiquitination and degradation of HPV E6 and E7, furthering the oncogenesis of HPV.

4 September 2025
Verified
Other
Open access
PDF file
NKNusrat Khan
Nusrat Khan
KAKeiko Akagi
Keiko Akagi
SJShiming Jiang
Shiming Jiang
JDJoe Dan Dunn
Joe Dan Dunn
BJBo Jiang
Bo Jiang
MGMaura L. Gillison
Maura L. Gillison
Read fraction of host-host and virus-host breakpoints in Tumor 1.

4 September 2025
Verified
Other
Open access
PDF file
NKNusrat Khan
Nusrat Khan
KAKeiko Akagi
Keiko Akagi
SJShiming Jiang
Shiming Jiang
JDJoe Dan Dunn
Joe Dan Dunn
BJBo Jiang
Bo Jiang
MGMaura L. Gillison
Maura L. Gillison
Definition of genomic segments flanking HPV integrants in Tumor 5.